• Pre-clinical data suggests ER antagonist fulvestrant (F) may be more effective in a low vs. high estrogen environment [1]
• EFECT showed no difference in progression free survival (PFS) between F & steroidal AI exemestane (E) in this setting (HR=0.96, 95%CI: 0.82-1.13; p=0.65) [2] • SoFEA combined F with anastrozole (F+A) in patients (pts) with acquired resistance to previous AI & compared with F alone & F vs. E. F+A was no better than F (HR=1.00, 95%CI: 0.83-1.21; p=0.98) nor F better than E (HR=0.95, 95%CI: 0.79-1.14; p=0.56) in terms of PFS [3] • Given differences in prior endocrine therapy/responsiveness within SoFEA & EFECT populations, an individual pt metaanalysis was conducted to explore potential subgroups sensitive to F 
